Panacell Biotech Reports Preclinical Success of Exosome Regenerative Therapy Platform for Pulmonary Fibrosis

Source: Panacell Biotech Pulmonary fibrosis is a devastating disease affecting over 10% of the population aged 50 and older, with a five-year survival rate reported to be below 40%. In the United States alone, approximately 30,000 patients die from the condition annually-a figure comparable to the annual mortality rate of breast cancer. Panacell Biotech (CEO Choi Seung Ho) announced that its…